Zacks.com on MSN5d
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority TagThe FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.
Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal juncture as it seeks to capitalize on the burgeoning market for ...
$221.55 million regulatory claim against FTX DM. The Court-approved “Claim Subordination Agreement” between the JOLs and the Commission enables the reprioritisation of the payment of all ...
$221.55 million regulatory claim against FTX DM. The Court-approved “Claim Subordination Agreement” between the JOLs and the Commission enables the reprioritisation of the payment of all ...
# The Supreme Court yesterday approved the Securities Commission’s bid to relegate its $221.55m claim against FTX behind those of the insolvent crypto exchange’s clients and other victims.
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
2019 was a landmark year for RWE that included the first ever FDA approval based on RWE alone, major cross-industry collaborations to develop standards, and new regulatory guidance on acceptable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback